Quell Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Translation & Innovation Hub 84 Wood Ln,...Phone Number
+44 2070969012Website
www.quell-tx.comRevenue
$23.6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Quell Therapeutics
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.Explore more
Quell Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Quell Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Quell Therapeutics
Check out if Quell Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Quell Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Quell Therapeutics recently announced quarterly report
Product Launch: Get notified when Quell Therapeutics launches new products
Check if Quell Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Quell Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Quell Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Quell Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Quell Therapeutics
Compare insights from companies similar to Quell Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Quell Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Quell Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Quell Therapeutics.
Quell Therapeutics financials insights
Gather financial insights about Quell Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$40M
Series B
$156M
Quell Therapeutics Tech Stack
A closer look at the technologies used by Quell Therapeutics
See more technologies
Most Recent Scoops
Hiring Plans
Quell Therapeutics has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Quell Therapeutics News & Media
Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today shared interim top-line data from its LIBERATE Phase 1/2 trial and provided an update on its broader clinical strategy – building on the validating insights from LIBERATE, Quell is now initiating the QEL-005 CHILL clinical trial in complex autoimmunity (see separate announcement today).Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025
London, UK – 25 October, 2025 – Quell Therapeutics Ltd (“Quell”), a pioneer in engineered T-regulatory (Treg) cell therapies for people with immune-mediated diseases, will present promising data from pre-clinical studies of QEL-005 that highlight its potential to treat complex autoimmune inflammatory diseases, such as Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc), at the American College of Rheumatology annual meeting (ACR Convergence 2025) to be held in Chicago, IL from 24–29 October.Quell Therapeutics Establishes World-Class Scientific Advisory Board
London, UK – 27 August, 2025 – Quell Therapeutics Ltd (“Quell”), a pioneer in engineered T-regulatory (Treg) cell therapies for people with immune-mediated diseases, announces the formation of its Scientific Advisory Board (SAB). The SAB comprises globally recognized leaders in Treg cell biology, engineering and manufacturing, immunology, autoimmune diseases and organ transplantation, and has been created to provide scientific and clinical guidance to Quell as it builds and advances an industryQuell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease
Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Quell Therapeutics
Sign Up For FreeTo access detailed company insights
Quell Therapeutics is the world leader in developing engineered T-regulatory (Treg) cell therapies that aim to harness, direct and optimize their immune suppressive properties to address serious medical conditions driven by the immune system.... Read More
